reports
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Michael B. Schäfer
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 04/30/2024
BHP's bid for Anglo American has confirmed interest from miners in copper in the context of increasingly challenged production and difficulties in fully completing projects. Anglo’s (Neutral) prospects in copper are now better valued and this is also the case for BHP (Neutral vs Underperform) although not so for Rio Tinto (Outperform vs Neutral). Downstream, Nexans and Montana Aerospace are our Top Picks (Outperform) vs Aurubis, Rexel and Prysmian (Neutral). - ...
TKA THYSSENKRUPP AG
DG VINCI SA
JMT JERONIMO MARTINS SGPS S.A.
GALP GALP ENERGIA SGPS SA CLASS B
ADS ADIDAS AG
MTX MTU AERO ENGINES AG
HO THALES SA
FORTUM FORTUM OYJ
WTB WHITBREAD PLC
DAI DAIMLER AG
QIA QIAGEN NV
RXL REXEL SA
VNA VONOVIA SE
CAP CAPGEMINI SE
NEM NEMETSCHEK SE
ABI ANHEUSER-BUSCH INBEV SA/NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STMN STRAUMANN HOLDING AG
- Michael B. Schäfer
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 30/04/2024
L’offre de BHP sur Anglo American a confirmé l’intérêt des minières pour le cuivre dans un contexte de tensions croissantes sur la production et de difficultés à faire aboutir les projets. Les perspectives d’Anglo (Neutre) dans le cuivre sont désormais mieux valorisées, c’est aussi le cas de BHP (Neutre vs Sous-performance) mais pas encore assez, selon nous, sur Rio Tinto (Surperformance vs Neutre). En aval, Nexans et Montana Aerospace sont nos valeurs préférées (Surperformance) vs Au...
TKA THYSSENKRUPP AG
DG VINCI SA
JMT JERONIMO MARTINS SGPS S.A.
GALP GALP ENERGIA SGPS SA CLASS B
ADS ADIDAS AG
MTX MTU AERO ENGINES AG
HO THALES SA
FORTUM FORTUM OYJ
WTB WHITBREAD PLC
DAI DAIMLER AG
QIA QIAGEN NV
RXL REXEL SA
VNA VONOVIA SE
CAP CAPGEMINI SE
NEM NEMETSCHEK SE
ABI ANHEUSER-BUSCH INBEV SA/NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STMN STRAUMANN HOLDING AG
- Oliver Metzger
- Stephan Wulf
Qiagen : Very solid Q1 results. FY 2024 guidance confirmed. Return to ...
>Solid Q1 figures above expectations and guidance - Qiagen reported a set of solid Q1 results. Sales came in at $459m, above our ($ 456m) and the consensus estimates ($ 458m). Y-o-y, sales declined as expected by 5%, reflecting challenging macro demand trends and predominantly burdened by declining instrument sales (-10% to $50m). Looking at CER sales of $ 462m, Q1 2024 came in some 1.5% as guided by the company ($ 455m).Adjusted operating income of $ 118m was sl...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Martin Marandon-Carlhian
- Stephane Houri
- Martin Marandon-Carlhian
- Stephane Houri
FP TOTAL SE
EQNR EQUINOR ASA
DBK DEUTSCHE BANK AG
FORTUM FORTUM OYJ
QIA QIAGEN NV
SCR SCOR SE
WHA WERELDHAVE N.V.
VOE VOESTALPINE AG
VASTN VASTNED RETAIL NV
BC8 BECHTLE AG
ASSA B ASSA ABLOY AB CLASS B
BP. BP P.L.C.
EVD CTS EVENTIM AG & CO. KGAA
AKZA AKZO NOBEL N.V.
ENR SIEMENS ENERGY AG
ECMPA EUROCOMMERCIAL PROPERTIES NV
SHUR SHURGARD SELF STORAGE LIMITED
- Oliver Metzger
- Stephan Wulf
Qiagen : 2023 results above estimates – 2024 guidance looks cautious
>Strong Q4 drives 2023 results above expectations - Thanks to a strong Q4 with sales CER up by 1% to $ 503m, despite a -43% sales decrease in Covid-19 product groups, Qiagen met its FY 2023 sales guidance of € 1.97bn - in contrast to our and the consensus expectations. The group also over-delivered on its CER adj. EPS target of $ 2.07 and achieved $ 2.09, vs our estimates of $ 2.06 and consensus of $ 2.05. The high 2023 revenue growth in non-Covid product groups (CER ...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
QIA QIAGEN NV
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
VLS VALNEVA SE
ALCAR CARMAT SA
GRF GRIFOLS S.A. CLASS A
ALINS INTRASENSE SA
ORY ORYZON GENOMICS
DIA DIASORIN S.P.A.
ADOC ADOCIA SA
ALVAL VALBIOTIS SA
BIM BIOMERIEUX SA
AFFLUENT MEDICAL SAS
ALMDP MEDESIS PHARMA SA
ALNFL NFL BIOSCIENCES SAS
ALTME TME PHARMA N.V.
ALVIN VINPAI
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
QIA QIAGEN NV
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
A1XAEB QUANTUM GENOMICS
VLS VALNEVA SE
ALCAR CARMAT SA
GRF GRIFOLS S.A. CLASS A
ALINS INTRASENSE SA
ORY ORYZON GENOMICS
DIA DIASORIN S.P.A.
ADOC ADOCIA SA
ALVAL VALBIOTIS SA
BIM BIOMERIEUX SA
AFFLUENT MEDICAL SAS
ALMDP MEDESIS PHARMA SA
ALNFL NFL BIOSCIENCES SAS
ALTME TME PHARMA N.V.
ALVIN VINPAI
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Charlotte Vaisse
- Jean-Baptiste Rouphael
- Oliver Metzger
GALP GALP ENERGIA SGPS SA CLASS B
HO THALES SA
RCO REMY COINTREAU SA
QIA QIAGEN NV
EN BOUYGUES SA
RAND RANDSTAD NV
ELE ENDESA S.A.
BAS BASF SE
SAN SANOFI
SIX2 SIXT SE
EDW EDP RENOVAVEIS SA
MAP MAPFRE SA
ABI ANHEUSER-BUSCH INBEV SA/NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
UN01 UNIPER SE
BP. BP P.L.C.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
STLA STELLANTIS N.V.
UMG UNIVERSAL MUSIC GROUP NV
STMN STRAUMANN HOLDING AG
DSFIR KONINKLIJKE DSM N.V.
- Charlotte Vaisse
- Jean-Baptiste Rouphael
- Oliver Metzger
GALP GALP ENERGIA SGPS SA CLASS B
HO THALES SA
RCO REMY COINTREAU SA
QIA QIAGEN NV
EN BOUYGUES SA
RAND RANDSTAD NV
ELE ENDESA S.A.
BAS BASF SE
SAN SANOFI
SIX2 SIXT SE
EDW EDP RENOVAVEIS SA
MAP MAPFRE SA
ABI ANHEUSER-BUSCH INBEV SA/NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
UN01 UNIPER SE
BP. BP P.L.C.
ARGX ARGEN-X SE
KBX KNORR-BREMSE AG
STLA STELLANTIS N.V.
UMG UNIVERSAL MUSIC GROUP NV
STMN STRAUMANN HOLDING AG
DSFIR KONINKLIJKE DSM N.V.
- Oliver Metzger
- Stephan Wulf
Qiagen : Q3 results ahead of guidance and estimates – 2023 guidance co...
>Q3 results beat guidance and consensus - Qiagen’s FX adjusted net sales came in at $ 470m, $ 5m above the company’s guidance and consensus and basically in line with our estimates of €472m. Compared with Q3 2022, nets sales were down c. 6%, as sales of Covid product groups declined by 59% to $ 34m. The Q3 2023 adjusted EBIT margin was 26.5% (28.7% in Q3 2022) slightly below our estimates of 26.9% and consensus of 27.1%. Adjusted EPS of $ 0.50 were down by nearly 6%, ...
Qiagen N.V.: 1 director
A director at Qiagen N.V. sold 29,365 shares at 44.000USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Andreas Riemann
- Andreas Riemann
- Oliver Metzger
- Stephan Wulf
Qiagen : Despite slightly lower FY 2023 guidance Qiagen’s key pillars ...
>Non-Covid product group sales increased by 9% in Q2 2023 - Q2 figures were basically in line with our and the consensus estimates. Reported EBIT came in at $ 105m (y-o-y -13.9%) compared with our estimates of $ 104m, adj. EBIT of $ 136m was -6.8% below the previous year’s figure but above our ($ 131m) and the consensus estimates of $ 134m. Adj. EPS of $ 0.51 was in line with Q2 2022 and the consensus and slightly below our estimate of $ 0.52. Compared with the compan...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.